文献速递神经肿瘤

现代直线加速器放疗治疗分泌型与非分泌型垂体腺瘤安全有效

Modern Linear Accelerator-Based Radiotherapy Is Safe and Effective in the Treatment of Secretory and Nonsecretory Pituitary Adenomas.
PubMed 文献 · World Neurosurg · 2021-12-28

该机构回顾性研究纳入2003至2017年140例垂体腺瘤患者(94例非分泌型、46例分泌型),接受现代直线加速器放疗(105例分次放疗、35例放射外科),中位随访5.35年。5年无进展生存率分泌型为95.3%、非分泌型为94.8%,5年内分泌控制率为50.0%。

要点

  • 5年无进展生存率分泌型垂体腺瘤为95.3%,非分泌型为94.8%。
  • 5年内分泌控制率为50.0%,与肿瘤剂量较高及手术次数相关。
  • 放疗后需任何垂体激素替代的患者从57.9%增至70.0%。

核心结论

  • 现代直线加速器放疗对垂体腺瘤患者的内分泌控制和局部控制安全有效。
  • 功能性与非功能性肿瘤的局部控制无差异,可能归因于更高的总剂量和每日图像引导。

研究设计与样本

  • 机构回顾性审查接受直线加速器放疗的垂体腺瘤患者,要求至少3年磁共振成像随访。
  • 2003年至2017年共140例垂体腺瘤患者(94例非分泌型、46例分泌型)接受直线加速器放疗,其中105例分次放疗、35例放射外科。
  • 中位随访5.35年;采用Kaplan-Meier法和Cox比例风险模型分析。

主要发现

  • 5年无进展生存率分泌型肿瘤为95.3%,非分泌型肿瘤为94.8%。
  • 多变量分析显示,计划靶区体积较大与更差的无进展生存相关(风险比2.87,95%置信区间1.01-8.21,P=0.049)。
  • 5年内分泌控制率为50.0%,与肿瘤剂量较高相关(风险比1.05,95%置信区间1.02-1.09,P=0.005),也与手术次数相关(风险比1.74,95%置信区间1.05-2.89,P=0.032)。
  • 放疗后需要任何垂体激素替代的患者从57.9%增至70.0%。

关键数值与推荐

  • 内分泌控制定义为未使用针对激素过多的药物情况下达到生化缓解。
  • 局部控制采用实体瘤疗效评价标准在监测磁共振成像上定义。
  • 无进展生存定义为存活且局部控制、分泌型垂体腺瘤无激素过多复发或加重的时间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant radiotherapy (RT) can help achieve local control (LC) and reduce hormonal overexpression for pituitary adenomas (PAs). Prior reports involved Gamma Knife or older linear accelerator (LINAC) techniques. The aim of this study was to report long-term outcomes for modern LINAC RT. METHODS: Institutional retrospective review of LINAC RT for PAs with minimum 3 years of magnetic resonance imaging follow-up was performed. Hormonal control was defined as biochemical remission in absence of medications targeting hormone excess. LC defined using Response Evaluation Criteria in Solid Tumors on surveillance magnetic resonance imaging. Progression-free survival defined as time alive with LC without return of or worsening hormonal excess from secretory PA. Kaplan-Meier and Cox proportional hazard models used. RESULTS: From 2003 to 2017, 140 patients with PAs (94 nonsecretory, 46 secretory) were treated with LINAC RT (105 fractionated RT, 35 radiosurgery) with median follow-up of 5.35 years. Techniques included fixed gantry intensity-modulated radiotherapy (51.4%), dynamic conformal arcs (9.3%), and volumetric modulated arc therapy (39.3%). Progression-free survival at 5 years was 95.3% for secretory tumors and 94.8% for nonsecretory tumors. Worse progression-free survival was associated with larger planning target volume on multivariable analysis (hazard ratio 2.87, 95% confidence interval 1.01-8.21, P = 0.049). Hormonal control at 5 years was 50.0% and associated with higher dose to tumor (hazard ratio 1.05, 95% confidence interval 1.02-1.09, P = 0.005) and number of surgeries (hazard ratio 1.74, 95% confidence interval 1.05-2.89, P = 0.032). Patients requiring any pituitary hormone replacement increased from 57.9% to 70.0% after RT. CONCLUSIONS: Modern LINAC RT for patients with PAs was safe and effective for hormonal control and LC. No difference in LC was noted for functional versus nonfunctional tumors, possibly owing to higher total dose and daily image guidance.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Janopaul-Naylor JR, Rupji M, Zhong J, et al. Modern Linear Accelerator-Based Radiotherapy Is Safe and Effective in the Treatment of Secretory and Nonsecretory Pituitary Adenomas. World Neurosurg. 2021. PMID: 34971832. doi:10.1016/j.wneu.2021.12.087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。